Published in Endocr Rev on February 01, 1987
Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J (1996) 3.59
Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J (2000) 2.96
Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor. Proc Natl Acad Sci U S A (1992) 1.98
Identification of a putative estrogen response element in the gene encoding brain-derived neurotrophic factor. Proc Natl Acad Sci U S A (1995) 1.92
An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens. Proc Natl Acad Sci U S A (1999) 1.79
Elevated insulin receptor content in human breast cancer. J Clin Invest (1990) 1.70
Epidermal growth factor replaces estrogen in the stimulation of female genital-tract growth and differentiation. Proc Natl Acad Sci U S A (1991) 1.60
Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest (1989) 1.56
Glucose-regulated protein 78 controls cross-talk between apoptosis and autophagy to determine antiestrogen responsiveness. Cancer Res (2012) 1.41
Mediation of estrogen mitogenic effect in human breast cancer MCF-7 cells by PC-cell-derived growth factor (PCDGF/granulin precursor). Proc Natl Acad Sci U S A (2001) 1.37
Covalent binding of the endogenous estrogen 16 alpha-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. Proc Natl Acad Sci U S A (1988) 1.32
Keratinocyte growth factor functions in epithelial induction during seminal vesicle development. Proc Natl Acad Sci U S A (1994) 1.31
Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes. Mol Cell Biol (1991) 1.30
Expression of epidermal growth factor receptor in breast carcinoma. J Clin Pathol (1990) 1.25
TGF beta suppresses casein synthesis in mouse mammary explants and may play a role in controlling milk levels during pregnancy. J Cell Biol (1993) 1.20
Promotion of murine hepatocarcinogenesis by testosterone is androgen receptor-dependent but not cell autonomous. Proc Natl Acad Sci U S A (1989) 1.15
Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am J Pathol (1999) 1.15
Co-stimulation of gastrointestinal tumour cell growth by gastrin, transforming growth factor alpha and insulin like growth factor-I. Br J Cancer (1991) 1.09
Cross talk between peptide growth factor and estrogen receptor signaling systems. Environ Health Perspect (1995) 1.05
Expression of Q227L-galphas in MCF-7 human breast cancer cells inhibits tumorigenesis. Proc Natl Acad Sci U S A (1998) 1.01
Genesis of prolactinomas: studies using estrogen-treated animals. Front Horm Res (2006) 1.00
p66Shc--a longevity redox protein in human prostate cancer progression and metastasis : p66Shc in cancer progression and metastasis. Cancer Metastasis Rev (2010) 0.99
A novel role of Shc adaptor proteins in steroid hormone-regulated cancers. Endocr Relat Cancer (2008) 0.88
Prostatic carcinogenesis evoked by cellular interaction. Environ Health Perspect (1988) 0.87
Different methylation of oestrogen receptor DNA in human breast carcinomas with and without oestrogen receptor. Br J Cancer (1990) 0.86
Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells. Proc Natl Acad Sci U S A (1992) 0.84
Mitogenic regulation of normal and malignant breast epithelium. Yale J Biol Med (1990) 0.82
Epidermal growth factor suppresses induction by progestin of the adhesion protein desmoplakin in T47D breast cancer cells. Breast Cancer Res (2004) 0.81
Oestrogen (ER) and progestin receptors (PR) in mammary tissue of the female dog: different receptor profile in non-malignant and malignant states. Br J Cancer (1988) 0.80
17-beta-estradiol increases mitogenic activity of medium from cultured preadipocytes of massively obese persons. J Clin Invest (1989) 0.79
p66Shc as a switch in bringing about contrasting responses in cell growth: implications on cell proliferation and apoptosis. Mol Cancer (2015) 0.79
Malignant progression of SV40-immortalised human milk epithelial cells. Br J Cancer (1993) 0.79
Expression of epidermal growth factor receptor (proto-oncogene c-erbB-1) and estrogen receptor in human breast carcinoma. An immunocytochemical study of 70 cases. Arch Gynecol Obstet (1993) 0.79
17beta-Oestradiol treatment modulates nitric oxide synthase activity in MDA231 tumour with implications on growth and radiation response. Br J Cancer (2002) 0.78
Modification of the rat uterine response to oestrogen and tamoxifen by thromboxane antagonists. Br J Pharmacol (1991) 0.78
Insulin-like growth factor 1 receptors in human breast tumour: localisation and quantification by histo-autoradiographic analysis. Br J Cancer (1992) 0.78
Role of estrogens and epidermal growth factor in hepatocellular carcinoma (HCC). Dig Dis Sci (1991) 0.78
Maternal flaxseed diet during pregnancy or lactation increases female rat offspring's susceptibility to carcinogen-induced mammary tumorigenesis. Reprod Toxicol (2007) 0.76
Insulin-like growth factor and epidermal growth factor signaling in breast cancer cell growth: focus on endocrine resistant disease. Anal Cell Pathol (Amst) (2015) 0.76
Fulvestrant reverses doxorubicin resistance in multidrug-resistant breast cell lines independent of estrogen receptor expression. Oncol Rep (2016) 0.75
Estrogen receptor expression in adrenocortical carcinoma. J Zhejiang Univ Sci B (2009) 0.75
Proliferative behaviour of an oestrogen sensitive rat mammary tumour: evidence for a paracrine interaction between tumour and stroma. Br J Cancer (1993) 0.75
Breast cancer (1) N Engl J Med (1992) 4.79
Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell (1987) 3.45
Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med (1995) 3.43
Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol (1992) 3.15
Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol (1990) 3.12
Clonogenic and nonclonogenic in vitro chemosensitivity assays. Cancer Treat Rep (1985) 2.97
Multicolour spectral karyotyping of mouse chromosomes. Nat Genet (1996) 2.90
erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst (1998) 2.85
Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem (2000) 2.47
Morphologic characterization of the pathway of transferrin endocytosis and recycling in human KB cells. Proc Natl Acad Sci U S A (1984) 2.42
c-Myc in breast cancer. Endocr Relat Cancer (2000) 2.32
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat (2001) 2.26
alpha 2-macroglobulin adsorbed to colloidal gold: a new probe in the study of receptor-mediated endocytosis. J Cell Biol (1981) 2.19
C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br J Cancer (2000) 2.14
Mechanism of action of glucocorticoids. Metabolism (1974) 2.04
Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. Science (1990) 2.00
Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. Cancer Res (1978) 1.97
Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J Biol Chem (1999) 1.93
Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute. J Clin Oncol (1992) 1.89
LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J Clin Invest (1998) 1.89
Psychosocial and physical outcomes of primary breast cancer therapy: mastectomy vs excisional biopsy and irradiation. Breast Cancer Res Treat (1983) 1.80
Amantadine and dansylcadaverine inhibit vesicular stomatitis virus uptake and receptor-mediated endocytosis of alpha 2-macroglobulin. Proc Natl Acad Sci U S A (1982) 1.76
Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol Endocrinol (1987) 1.72
Breast conservation versus mastectomy: distress sequelae as a function of choice. J Clin Oncol (1989) 1.70
Isolation and characterization of a highly enriched preparation of receptosomes (endosomes) from a human cell line. Proc Natl Acad Sci U S A (1983) 1.68
Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol (1989) 1.65
Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther (2001) 1.64
Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity. J Biol Chem (1999) 1.62
Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines. Proc Natl Acad Sci U S A (1987) 1.61
Breast cancer risk in rats fed a diet high in n-6 polyunsaturated fatty acids during pregnancy. J Natl Cancer Inst (1996) 1.60
Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance. Mol Endocrinol (1988) 1.59
Secretion of an insulin-like growth factor-I-related protein by human breast cancer cells. Cancer Res (1986) 1.58
Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am J Pathol (2001) 1.57
Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res (1990) 1.57
Oestrogen-responsive human breast cancer in long term tissue culture. Nature (1975) 1.56
The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med (1978) 1.54
Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res (1987) 1.54
Regulation of the activity of matriptase on epithelial cell surfaces by a blood-derived factor. Eur J Biochem (2001) 1.49
Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis. Oncogene (2008) 1.48
Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines. J Natl Cancer Inst (2000) 1.46
Prelysosomal divergence of transferrin and epidermal growth factor during receptor-mediated endocytosis. Biochemistry (1983) 1.46
Characterization of estrogen responsive transforming activity in human breast cancer cell lines. Cancer Res (1986) 1.44
Matrix metalloproteinase inhibitors. Invest New Drugs (1997) 1.43
Estrogen-induced factors of breast cancer cells partially replace estrogen to promote tumor growth. Science (1986) 1.41
Breast cancer (2). N Engl J Med (1992) 1.39
Growth factors in breast cancer. Endocr Rev (1995) 1.37
Characterization of a novel, membrane-bound, 80-kDa matrix-degrading protease from human breast cancer cells. Monoclonal antibody production, isolation, and localization. J Biol Chem (1997) 1.36
Effect of P-glycoprotein expression on sensitivity to hormones in MCF-7 human breast cancer cells. J Natl Cancer Inst (1992) 1.36
Growth factor messenger RNA expression by human breast fibroblasts from benign and malignant lesions. Cancer Res (1991) 1.36
Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer. Cancer Res (1979) 1.35
Receptor-mediated endocytosis in cultured fibroblasts: cryptic coated pits and the formation of receptosomes. J Histochem Cytochem (1981) 1.35
Changes in multiple or sequential estrogen receptor determinations in breast cancer. Cancer (1980) 1.34
Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. Cancer Res (1993) 1.32
Hormone responsive human breast cancer in long-term tissue culture: effect of insulin. Proc Natl Acad Sci U S A (1976) 1.32
MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res (1993) 1.32
Insulin-like growth factor II mRNA expression in human breast cancer. Cancer Res (1988) 1.32
Effects of antiestrogens on the estrogen-regulated pS2 RNA and the 52- and 160-kilodalton proteins in MCF7 cells and two tamoxifen-resistant sublines. J Biol Chem (1984) 1.31
Regulation of the estrogen receptor in MCF-7 cells by estradiol. Mol Endocrinol (1988) 1.31
Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production. J Natl Cancer Inst (1993) 1.30
Dual regulation of proliferation and apoptosis: c-myc in bitransgenic murine mammary tumor models. Oncogene (2000) 1.29
Association between steroid hormone receptor status and disease-free interval in breast cancer. Cancer Treat Rep (1979) 1.27
A recurring pattern of chromosomal aberrations in mammary gland tumors of MMTV-cmyc transgenic mice. Genes Chromosomes Cancer (1999) 1.26
Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo. J Natl Cancer Inst (2001) 1.26
Transfection of v-rasH DNA into MCF-7 human breast cancer cells bypasses dependence on estrogen for tumorigenicity. Science (1985) 1.26
Angiopoietin-1 and its receptor Tie-2 participate in the regulation of capillary-like tubule formation and survival of endothelial cells. Microvasc Res (1999) 1.26
Estrogen receptor in adult male rat liver. Endocrinology (1978) 1.26
Oestrogen receptors in human malignant melanoma. Lancet (1976) 1.26
Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo. Cancer Res (1999) 1.25
Expression and function of angiopoietin-1 in breast cancer. Br J Cancer (2000) 1.24
Oncogene-induced basement membrane invasiveness in human mammary epithelial cells. Clin Exp Metastasis (1994) 1.24
Overexpression of KAI1 suppresses in vitro invasiveness and in vivo metastasis in breast cancer cells. Cancer Res (2001) 1.23
Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17 beta-estradiol or v-Ha-ras oncogene. Proc Natl Acad Sci U S A (1987) 1.22
Competitive protein binding assay for methotrexate. Proc Natl Acad Sci U S A (1975) 1.21
Tamoxifen retinopathy. Cancer Treat Rep (1978) 1.21
Effect of estrogens and antiestrogens on growth-regulatory enzymes in human breast cancer cells in tissue culture. Cancer Res (1985) 1.20
Selection and characterization of a breast cancer cell line resistant to the antiestrogen LY 117018. Endocrinology (1985) 1.20
Induction of epidermal growth factor-related polypeptides by 17 beta-estradiol in MCF-7 human breast cancer cells. Endocrinology (1986) 1.19
Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses. Br J Cancer (2004) 1.19
Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo. Proc Natl Acad Sci U S A (1989) 1.19
Breast cancer (3). N Engl J Med (1992) 1.18
Glucocorticoid-binding proteins in human acute lymphoblastic leukemic blast cells. J Clin Invest (1973) 1.17
Binding and internalization of 125I-alpha 2-macroglobulin by cultured fibroblasts. J Biol Chem (1981) 1.17
Dihydrofolate reductase gene amplification and possible rearrangement in estrogen-responsive methotrexate-resistant human breast cancer cells. J Biol Chem (1982) 1.17
Additive effects of c-erbB-2, c-Ha-ras, and transforming growth factor-alpha genes on in vitro transformation of human mammary epithelial cells. Mol Carcinog (1992) 1.17
High-dose chemotherapy plus autologous bone marrow transplantation for metastatic breast cancer. N Engl J Med (2000) 1.17
Quantitative estrogen receptor analyses: the response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free interval. Cancer (1980) 1.15
Adjuvant chemotherapy in males with cancer of the breast. Am J Clin Oncol (1987) 1.14
Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol (1989) 1.14